Home » IgAN

Tag Archives: IgAN

DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path

Posted on by — No Comments ↓

We have to thank Liu and colleagues for a thorough review of pharmaceutical development activities in China and elsewhere during the last decade.[1]  The authors reviewed a total of 34,844 Phase 1-3 trials, showing a significant uptick in studies initiated by Chinese companies.  Compared to 2015, trial numbers have steadily Continue reading DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path→

The Tiragolumab Saga & Tifacogin Flash-Backs

Posted on by — No Comments ↓

A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1]  The science writer interviewed a group of insiders that had a lead role in the development of Continue reading The Tiragolumab Saga & Tifacogin Flash-Backs→

IgAN Therapeutics – The Race is On

Posted on by — No Comments ↓

Is there a new trend in the journal world:  publication of interim analysis (IA) results? The NEJM recently published two articles back to back, both highlighting 9 month ‘interim’ data from Phase 3 pivotal trials in IgAN. The primary efficacy endpoint used in either study was UPCR at 9 months, Continue reading IgAN Therapeutics – The Race is On→